Subscribe to Newsletter
Discovery & Development Drug Discovery

Down with the Resistance

Are all antibiotics doomed to eventual impotence? New work from Oxford could change the game by defeating resistance itself.

Business & Regulation Business Practice

Time Will Always Tell

| Maryam Mahdi

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.

Manufacture Technology and Equipment

The Next Level: Pharma Meets Video Game Tech

| Stephanie Vine

Get ready for medicine making level 2 as video games come to healthcare backed with clinical trial data that demonstrate efficacy.

Discovery & Development Drug Discovery

A Little Byte of Life

Thorben Seeger wants to democratize the data held by the world’s leading genomic institutions. But what exactly does he mean by “democratize”?

Business & Regulation Profession

Thursday is the Deadline

Nominations and voting for the Power List, Company of the Year Awards, and Innovation Awards ends on Thursday 17 March

Discovery & Development Drug Discovery

Anthrax: an Unlikely Ally

| Angus Stewart

Boston bioscientists have found an unlikely ally in anthrax toxins, which could form the basis for a new kind of painkiller.

Manufacture Small Molecules

Celebrating the Small Molecule Space: Download Our eBook

Our eBook features drug development stories, a drive for novel excipients, new technologies, and more.

Business & Regulation Digital Technologies

Mapping Biochemistry’s Dark Matter: Lessons Learned With Viswa Colluru

| Viswa Colluru

Enveda Biosciences Founder Viswa Colluru shares the lessons he has learned whilst charting the vast terra incognita of nature’s chemical structure

Manufacture Digital Technologies

Industry 4.0: The Invisible Hand

| Angus Stewart

Yvonne Duckworth lays out insights into Pharma 4.0 gleaned in a recent report by CRB. VR, AR, AI: is it more than just alphabet soup?

Discovery & Development Business Practice

“We Want to Return to the Lab”: How the Russian Invasion Has Disrupted Drug Discovery in Ukraine

| Angus Stewart

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register